-

Agilent Names August Specht as Chief Technology Officer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced August Specht, Ph.D., has been named the company’s Chief Technology Officer. Specht, previously vice president of Global R&D for the Chromatography and Mass Spectrometry Division at Thermo Fisher Scientific, will join Agilent on June 9.

“We are thrilled to welcome August Specht to the Agilent team as we further accelerate the pace of innovation in an ever-changing world through our Ignite Transformation.”

Share

“We are thrilled to welcome August Specht to the Agilent team as we further accelerate the pace of innovation in an ever-changing world through our Ignite Transformation,” said Padraig McDonnell, Agilent president and CEO. “August brings more than 25 years of experience designing, developing, and marketing analytical instruments, software, and consumables that support scientific advancement around the world. His work reflects a deep understanding of the scientific community’s evolving needs and a commitment to delivering innovative solutions that help customers bring great science to life.”

Prior to his role as vice president of Global R&D for the Chromatography and Mass Spectrometry Division at Thermo Fisher, Specht served in a variety of leadership roles in R&D, product management, strategy, and business development at both Thermo Fisher and Varian Instruments.

August holds a Bachelor of Science (Honors) in Chemistry from Queen’s University in Canada, a doctorate in Analytical Chemistry from the University of British Columbia, and an MBA from the University of California, Berkeley.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact:
Andréa Topper
+1 408-709-0060
andrea.topper@agilent.com

Industry:

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB
Release Versions
English

Contacts

Media Contact:
Andréa Topper
+1 408-709-0060
andrea.topper@agilent.com

Social Media Profiles
Agilent's Facebook
Agilent's Instagram
Agilent's LinkedIn
More News From Agilent Technologies Inc.

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...

Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tec...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...
Back to Newsroom